ClinicalTrials.Veeva

Menu

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Cairo University (CU) logo

Cairo University (CU)

Status and phase

Completed
Phase 2
Phase 1

Conditions

Systemic Lupus Erythematosis

Treatments

Drug: Hydrocortisone
Drug: Cyclophosphamide
Drug: Hydroxychloroquine

Study type

Interventional

Funder types

Other

Identifiers

NCT02756546
BC (1016)

Details and patient eligibility

About

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult systemic lupus erythematosis patients

Exclusion criteria

  • Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Control
No Intervention group
Description:
Healthy volunteers
Patients
Active Comparator group
Description:
SLE patients further divided into mild and severe patients
Treatment:
Drug: Hydrocortisone
Drug: Hydroxychloroquine
Drug: Cyclophosphamide

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems